Renal Cell Carcinoma: From Diagnostic to Therapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 2503

Special Issue Editors


E-Mail Website
Guest Editor
Department of Urology, The University of California, San Diego, CA 92037, USA
Interests: kidney cancer; partial nephrectomy; radical nephrectomy; robotic surgery

E-Mail Website
Guest Editor
Division of Urology, Department of Surgery, SSM St Louis University, St Louis, MO 63110, USA
Interests: urologic oncology; robotic surgery; nephrectomy; prostatectomy; cystectomy

Special Issue Information

Dear Colleagues,

Kidney cancer is the 14th most common cancer worldwide, with an annual incidence of greater than 400,000 cases and over 150,000 deaths. Recent advancements include the adoption of active surveillance for small renal masses, robotic surgery, and improvements in systemic therapy; however, much progress remains to improve early detection of localized disease and survival outcomes.

In this Special Issue, we are honored to invite researchers and clinicians that specialize in kidney cancer to present topics of interest across the spectrum of kidney cancer diagnosis and treatment. We aim to increase the knowledge base of the field by highlighting novel changes to kidney cancer management. Original investigations and review articles are welcome.

Potential topics include, but are not limited to, the following:

  • Advances in diagnosis or screening for kidney cancer;
  • Stage migration of disease at diagnosis;
  • Novel aspects to surgical management;
  • Minimally invasive ablative techniques for localized disease;
  • Integration of biomarkers for diagnosis and follow-up after treatment of localized disease;
  • Management of variant histology;
  • Surgical management of metastatic kidney cancer, including neoadjuvant therapy and oligometastatic disease;
  • Timing of cytoreductive nephrectomy after systemic therapy;
  • Systemic therapy for metastatic kidney cancer and sequencing of therapy.

We thank the authors in advance for their submissions.

Prof. Dr. Ithaar H. Derweesh
Dr. Zachary A. Hamilton
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • clinical practice patterns
  • diagnosis
  • kidney cancer
  • metastasis
  • renal cell carcinoma
  • renal mass
  • staging
  • systemic therapy
  • surveillance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 547 KiB  
Article
Renal Cell Carcinoma with Venous Tumor Thrombus: 15 Years of Experience in an Oncology Center
by Gabriel Faria-Costa, Rui Freitas, Isaac Braga, Maria Ana Alzamora, Sanches Magalhães, João Carvalho, Jorge Correia, Vítor Moreira Silva, Francisco Lobo, Rui Henrique and António Morais
J. Clin. Med. 2024, 13(20), 6260; https://doi.org/10.3390/jcm13206260 - 20 Oct 2024
Cited by 1 | Viewed by 1250
Abstract
Background: The purpose of this study is to report the experience of a single Portuguese oncology center in the management of patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT). Methods: This is a retrospective analysis of all patients with RCC [...] Read more.
Background: The purpose of this study is to report the experience of a single Portuguese oncology center in the management of patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT). Methods: This is a retrospective analysis of all patients with RCC and VTT surgically treated in our center between 2008 and 2023. Only patients with VTT up to level III (Mayo Clinic classification) were included. Patient, tumor characteristics and peri-operative outcome data were registered. Administration of systemic therapy was performed upon progression. Survival analysis was conducted with the collected data. Results: A total of 64 patients (n = 16 women) were included in this study. The mean age at diagnosis was 66.3 ± 10.7 years old. The VTT level was 0, I, II and III in 40 (62.5%), 12 (18.7%), 6 (9.4%) and 6 (9.4%) patients, respectively. Nine patients (14.1%) had distant metastasis at diagnosis. No peri-operative deaths occurred, and the major complication rate was 3.1%. Histology revealed 98.4% of clear cell RCC, with sarcomatoid differentiation present in 12.5% of the cases. A negative margin status was achieved in 54 (84.4%) patients. Systemic therapy was administered in 24 (37.5%) patients during follow-up. The median progression-free (PFS), cancer-specific (CSS) and overall (OS) survival were 23, 60 and 48 months, respectively. In multivariable analysis, significant predictors of CSS were tumor size, sarcomatoid differentiation and collecting system invasion. Conclusions: Radical nephrectomy with VTT excision up to level III is a feasible and safe procedure. Patients with large tumor size, sarcomatoid differentiation and collecting system invasion are at the highest risk and should be closely monitored. Full article
(This article belongs to the Special Issue Renal Cell Carcinoma: From Diagnostic to Therapy)
Show Figures

Figure 1

Review

Jump to: Research

12 pages, 367 KiB  
Review
Utilization of Partial Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma
by Nicholas Hauser, Julian Giakas, Hunter Robinson, Facundo Davaro and Zachary Hamilton
J. Clin. Med. 2024, 13(19), 5767; https://doi.org/10.3390/jcm13195767 - 27 Sep 2024
Viewed by 944
Abstract
Objectives: Cytoreductive nephrectomy for metastatic renal cell carcinoma (mRCC) is a standard of care. Partial nephrectomy (PN) in the setting of metastatic disease is an uncommon occurrence, and we aimed to characterize its utilization in a modern cohort. Methods: The National Cancer Database [...] Read more.
Objectives: Cytoreductive nephrectomy for metastatic renal cell carcinoma (mRCC) is a standard of care. Partial nephrectomy (PN) in the setting of metastatic disease is an uncommon occurrence, and we aimed to characterize its utilization in a modern cohort. Methods: The National Cancer Database was reviewed for patients with mRCC from 2010 to 2017. Patients with cTanyNanyM1 who underwent cytoreductive surgery in the form of PN or radical nephrectomy (RN) were compiled. Our primary outcome was survival outcome for patients who underwent PN compared to RN. Secondary outcomes included 30-day readmission, length of stay, and survival outcomes. Results obtained: A total of 13,896 patients with mRCC who underwent cytoreductive surgery were identified. In total, 13,242 underwent RN and 654 underwent PN. The RN population was more likely to have cN positive disease, while the PN population was more likely to have cT1 disease. Length of stay, readmission and 30-day mortality were not significantly different between PN and RN, but overall mortality and 90-day mortality favored PN (p < 0.001). Cox regression for death showed PN with improved overall survival (HR 0.782, p < 0.001). Logistic regression for predictors of cytoreductive PN revealed cT1 and cN0 as significant factors. Overall survival, as seen on KM analysis, identified that PN exhibited improved 2-year (67.1% vs. 52.0%) and 5-year (40.7% vs. 29.2%) overall survival relative to RN (p < 0.001). Conclusions: PN is an infrequent treatment with mRCC and its utilization is stable from 2010 to 2017. Overall survival is significantly better for those undergoing PN, likely due to their favorable oncologic disease characteristics. Full article
(This article belongs to the Special Issue Renal Cell Carcinoma: From Diagnostic to Therapy)
Show Figures

Figure 1

Back to TopTop